The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
Open accessAbstract
Background: ‘No evidence of disease activity’ (NEDA), defined as absence of magnetic resonance imaging activity (T2 and/or gadolinium-enhanced T1 lesions), relapses and disability progression (‘NEDA-3’), is used as a comprehensive measure of treatment response in relapsing multiple sclerosis (RMS), but is weighted towards inflammatory activity. Accelerated brain volume loss (BVL) occurs in RMS and is an objective measure of disease worsening and progression. Objective: To assess the contribution of individual components of NEDA-3 and the impact of adding BVL to NEDA-3 (‘NEDA-4’) Methods: We analysed data pooled from two placebo-controlled phase 3 fingolimod trials in RMS and assessed NEDA-4 using different annual BVL mean rate thresholds (0.2%–1.2%). Results: At 2 years, 31.0% (217/700) of patients receiving fingolimod 0.5 mg achieved NEDA-3 versus 9.9% (71/715) on placebo (odds ratio (OR) 4.07; p < 0.0001). Adding BVL (threshold of 0.4%), the respective proportions of patients achieving NEDA-4 were 19.7% (139/706) and 5.3% (38/721; OR 4.41; p < 0.0001). NEDA-4 status favoured fingolimod across all BVL thresholds tested (OR 4.01–4.41; p < 0.0001). Conclusion: NEDA-4 has the potential to capture the impact of therapies on both inflammation and neurodegeneration, and deserves further evaluation across different compounds and in long-term studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E.-W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,644
Self-citationOral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,204
Self-citationCortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Frischer, J. M., Bramow, S., Dal-Bianco, A., Lucchinetti, C. F., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., & Lassmann, H. (2009) · Brain · doi:10.1093/brain/awp070 · Cited by 1,450
Multiple Sclerosis: Current Knowledge and Future Outlook
Kamm, C. P., Uitdehaag, B. M., & Polman, C. H. (2014) · European Neurology · doi:10.1159/000360528 · Cited by 1,010
Calabresi, P. A., Radue, E.-W., Goodin, D., Jeffery, D., Rammohan, K. W., Reder, A. T., Vollmer, T., Agius, M. A., Kappos, L., Stites, T., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70049-3 · Cited by 825
Self-citationAssociation between pathological and MRI findings in multiple sclerosis
Filippi, M., Rocca, M. A., Barkhof, F., Brück, W., Chen, J. T., Comi, G., DeLuca, G., De Stefano, N., Erickson, B. J., Evangelou, N., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70003-0 · Cited by 486
Self-citationHavrdova, E., Galetta, S., Hutchinson, M., Stefoski, D., Bates, D., Polman, C. H., O'Connor, P. W., Giovannoni, G., Phillips, J. T., Lublin, F. D., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70021-3 · Cited by 471
Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort
Rotstein, D. L., Healy, B. C., Malik, M. T., Chitnis, T., & Weiner, H. L. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.3537 · Cited by 418
Eight-year follow-up study of brain atrophy in patients with MS
Fisher, E., Rudick, R. A., Simon, J. H., Cutter, G., Baier, M., Lee, J. C., Miller, D., Weinstock-Guttman, B., Mass, M. K., Dougherty, D. S., et al. (2002) · Neurology · doi:10.1212/01.wnl.0000036271.49066.06 · Cited by 374
Cited by
Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
Silent progression in disease activity–free relapsing multiple sclerosis
University of California, S. F. M. T., Cree, B. A. C., Hollenbach, J. A., Bove, R., Kirkish, G., Sacco, S., Caverzasi, E., Bischof, A., Gundel, T., Zhu, A. H., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25463 · Cited by 465
Self-citationLong‐term evolution of multiple sclerosis disability in the treatment era
University of California, S. F. M. T., Cree, B. A. C., Gourraud, P., Oksenberg, J. R., Bevan, C., Crabtree‐Hartman, E., Gelfand, J. M., Goodin, D. S., Graves, J., Green, A. J., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24747 · Cited by 440
Self-citationKappos, L., Fox, R. J., Burcklen, M., Freedman, M. S., Havrdová, E. K., Hennessy, B., Hohlfeld, R., Lublin, F., Montalban, X., Pozzilli, C., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.0405 · Cited by 228
Self-citationUher, T., McComb, M., Galkin, S., Srpova, B., Oechtering, J., Barro, C., Tyblova, M., Bergsland, N., Krasensky, J., Dwyer, M., et al. (2021) · Multiple Sclerosis Journal · doi:10.1177/1352458520912379 · Cited by 86
Metadata
- Authors
- Kappos, L., De Stefano, N., Freedman, M. S., Cree, B. A., Radue, E.-W., Sprenger, T., Sormani, M. P., Smith, T., Häring, D. A., Piani Meier, D., & Tomic, D.
- Venue
- Multiple Sclerosis Journal
- Publisher
- SAGE Publications
- Published
- 2016-07-19
- Volume
- 22
- Issue
- 10
- Pages
- 1297-1305
- ISSN
- 1352-4585 (ISSN-L)
- 1477-0970
- OpenAlex
- W2173315418
- Cited by
- 289
- References
- 29
- FWCI
- 34.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis. https://app.cochat.ai/papers/10.1177/1352458515616701
- The paper
- Kappos, L., De Stefano, N., Freedman, M. S., Cree, B. A., Radue, E.-W., Sprenger, T., Sormani, M. P., Smith, T., Häring, D. A., Piani Meier, D., & Tomic, D. (2016). Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis. Multiple Sclerosis Journal. https://doi.org/10.1177/1352458515616701
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.